State of the Large Intestine Microbiota in Patients with Type 1 Diabetes Mellitus Depending on the Severity of Clinical Course
Background. Type 1 diabetes mellitus (DM) results in the development and unfavorable clinical course of chronic inflammatory diseases, including those of ENT organs. Aim of the study — to explore the species composition and population level of the large intestine microflora in patients with type 1 DM depending on the severity of its clinical course. Materials and methods. By means of bacteriological and mycological methods, we have examined the content of the large intestine cavity in 50 patients aged 15 to 60 years with moderate and severe DM type 1, as well as in 30 apparently healthy individuals of the same age, who considered themselves to be healthy and were not affected by any diseases during the previous six months. The severe form of DM was diagnosed in 39 of 50 patients, and the clinical course of moderate severity — in 11 patients. Results. In moderate and severe course of type 1 DM, the deficiency of autochtonous bacteria of the genus Bifidobacterium, Lactobacillus, Peptostreptococcus, Enterococcus is formed in the content of the large intestine cavity, they are the most important by their representation in the large intestine microbiocenosis. Against this background, there is a contamination of the large intestine cavity with pathogenic (E.coli Hly+, EPEC) and opportunistic (Enterobacter, Citrobacter, Serratia, Proteus) enterobacteria, as well as opportunistic bacteria of the genus Bacteroides, Clostridium, P.niger, Staphylococcus, and yeast-like fungi of the Candida genus reaching a high population level. Conclusions. In the microbiocenosis of the large intestine cavity of patients with type 1 DM, there is a significant increase in the level of enterotoxigenic and enterotoxic (61.38 %) and opportunistic bacteria (71.24 %). A change of the species composition, Berger-Parker dominance index, constancy index results in the changes in a role of each component of the large intestine microbiocenosis of patients with type 1 DM both of a moderate and, to a greater extent, of severe course. In the large intestine cavity of patients with moderate and severe DM type 1, there is a significant (p < 0.05–0.001) deficiency of obligate bacteria of Bifidobacterium genus — 50.04 %, Lactobacillus — 34.82 %, Peptostreptococcus — 16.0 %, Enterococcus — 11.68 %. The more severe the clinical course, the more pronounced the deficiency, and a clear pattern of a decreased role of Bifidobacterium and Lactobacterium in the large intestine microbiocenosis is prognosticated. The findings are the reason to study the efficacy of probiotics in a comprehensive treatment of patients with type 1 DM before, after and 3 months after the treatment on the basis of the analysis of the species composition and population level of the large intestine microflora, as well as to work out the therapeutic modality for purulent sinusitis in patients with type 1 DM with inclusion of probiotics into the schemes of a comprehensive treatment.
Full Text:PDF (Українська)
Mazur ОО, Plaksyvyi OG, Pashkovska NV, Bilooka IO. The state of microbiota of the large intestine in patients with type 1 diabetes mellitus depending on the age and duration of the disease // International Journal of Endocrinology. 2016;3(75):19-24. Ukrainian.
Gavrylenko YuV., Laiko AA., Golovnia O.M. . [Tonsils microbiocenosis in children with type 1 diabetes with chronic tonsillitis given]. Journal of ear, nose and throat diseases. 2014(5): P.49-54. Ukrainian.
Conlon M, Bird A. The impact of diet and lifestyle on gut microbiota and human health. Nutrients.2014;7:17–44. doi: 10.3390/nu7010017.
Mejía-León M.E., de la Barca C. Diet, microbiota and immune system in type 1 diabetes development and evolution // Nutrients. 2015;7(11):9171–9184. doi: 10.3390/nu7115461
Gülden E, Wong FS, Wen L. The gut microbiota and Type 1 Diabetes. Clin Immunol. 2015;159(2):143-53. doi: 10.1016/j.clim.2015.05.013.
He C, Shan Y, Song W. Targeting gut microbiota as a possible therapy for diabetes. Nutr Res. 2015;35(5):361-7. doi: 10.1016/j.nutres.2015.03.002.
Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, Hu C, Wong FS, Szot GL, Bluestone JA, Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature. 2008;455:1109–1113. doi: 10.1038/nature07336.
Vaarala O. Is the origin of type 1 diabetes in the gut? Immunol. Cell Biol. 2012;90:271–276. doi: 10.1038/icb.2011.115.
Vaarala O, Atkinson MA, Neu J. The “perfect storm” for type 1 diabetes: The complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes. 2008;57:2555–2562. doi: 10.2337/db08-0331.
Virtanen SM, Nevalainen J, Kronberg-Kippilä C, Ahonen S, Tapanainen H, Uusitalo L, Takkinen H-M, Niinistö S, Ovaskainen M-L, Kenward MG. Food consumption and advanced β cell autoimmunity in young children with HLA-conferred susceptibility to type 1 diabetes: A nested case-control design. Am. J. Clin. Nutr. 2012;95:471–478. doi: 10.3945/ajcn.111.018879.
Davis-Richardson A, Triplett E. A model for the role of gut bacteria in the development of autoimmunity for type 1 diabetes. Diabetologia. 2015;58:1386–1393. doi: 10.1007/s00125-015-3614-8.
Giongo A, Gano KA, Crabb DB, Mukherjee N, Novelo LL, Casella G, Drew JC, Ilonen J, Knip M, Hyoty H. Toward defining the autoimmune microbiome for type 1 diabetes. ISME J. 2011;5:82–91. doi: 10.1038/ismej.2010.92.
De Goffau MC, Luopajärvi K, Knip M, Ilonen J, Ruohtula T, Härkönen T, Orivuori L, Hakala S, Welling GW, Harmsen HJ. Fecal microbiota composition differs between children with β-cell autoimmunity and those without. Diabetes. 2013;62:1238–1244. doi: 10.2337/db12-0526.
Alkanani AK, Hara N, Gottlieb PA, Robertson CE, Wagner BD, Frank DN, Zipris D. Alterations in intestinal microbiota correlate with susceptibility to type 1 diabetes. Diabetes. 2015;64:3510–3520. doi: 10.2337/db14-1847.
Murri M, Leiva I, Gomez-Zumaquero JM, Tinahones F, Cardona F, Soriguer F, Queipo-Ortuno MI. Gut microbiota in children with type 1 diabetes differs from that in healthy children: A case-control study. BMC Med. 2013;11 doi: 10.1186/1741-7015-11-46.
Skyler JS. Toward primary prevention of type 1 diabetes. JAMA. 2015;313:1520–1521. doi: 10.1001/jama.2015.2054.
This work is licensed under a Creative Commons Attribution 4.0 International License.
© "Publishing House "Zaslavsky", 1997-2019